Angelica Welch

James B. Yu, MD, discusses techniques with radiation therapy, potential roadblocks, and the importance of genomic testing in treating patients with prostate cancer.

Guru P. Sonpavde, MD, navigates through the treatment landscape of urothelial carcinoma.

Bradley J. Monk, MD, FACOG, FACS, discusses the promise of new therapies and regimens in patients with ovarian cancer in the recurrent setting.

Bradley A. McGregor, MD, discusses the growth of combination therapy in the treatment of patients with kidney cancer.

Keith Stewart, MB, ChB, discusses the role of stem cell transplant, minimal residual disease testing, and maintenance therapy in the treatment of patients with multiple myeloma.

Michael Rosenzweig, MD, discusses emerging treatment options for patients with immunoglobulin light chain amyloidosis such as daratumumab and NEOD001.

Gary H. Lyman, MD, FASCO, discusses ASCO's statement outlining the organization’s commitment to education and guidance regarding the use of biosimilars in the treatment of patients with cancer.

Nitya Nathwani, MD, highlights current treatment options for transplant-ineligible multiple myeloma, as well as combinations on the horizon.

Robert L. Ferris, MD, PhD, discusses the implications of the updated findings from the phase III CheckMate-141 trial in squamous cell carcinoma of the head and neck.

Hatem Soliman, MD, discusses the potential role of immunotherapy in triple-negative breast cancer.

Alexander Drilon, MD, discusses genomic drivers in non–small cell lung cancer as well as the current treatment options for patients who harbor those mutations.

C. Ola Landgren, MD, PhD, shares his insight on CAR T-cell therapy, sequencing, and triplet and quadruplet regimens in myeloma.

Koen van Besien, MD, PhD, shares his insights on challenges with bone marrow transplant and on the potential future for these technologies in a time when the landscape is undergoing many changes.

Tanios Bekaii-Saab, MD, sheds light on the recent advances in the treatment of patients with hepatocellular carcinoma.

Leif Bergsagel, MD, discusses the treatment evolution for patients with relapsed/refractory multiple myeloma.

Ari VanderWalde, MD, explains his trepidation with combinations of chemotherapy and immunotherapy in NSCLC.

Hyung L. Kim, MD, discusses perioperative systemic therapy for patients with kidney cancer.

Ramamoorthy Nagasubramanian, MD, discusses the results of the phase I/II study of larotrectinib in pediatric patients.

Michael Birrer, MD, PhD, discusses the effect that PARP inhibitors have had on the treatment of ovarian cancer, and the potential for combinations with these agents.

Jae H. Park, MD, discusses the impact of agents such as blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel on the treatment of acute lymphoblastic leukemia.

Stuart L. Goldberg, MD, discusses the management of patients with acute myeloid leukemia as well as those with myelodysplastic syndrome.

Manish A. Shah, MD, discusses the advancements being made in the treatment of patients with advanced gastric and gastroesophageal junction cancer.

Shubham Pant, MD, shares his insight on the future direction of the treatment landscape of colorectal cancer.

Robert B. Den, MD, discusses bone-targeting agents in prostate cancer and the potential future of combinations.

Edward S. Kim, MD, recaps the findings from the PACIFIC study of durvalumab and discussed the treatment of patients with stage III NSCLC.

Reshma Mahtani, DO, discusses the tolerability of CDK 4/6 inhibitors for the treatment of patients with metastatic breast cancer.

Chad Pecot, MD, discusses the rapidly growing area of combination immunotherapy in non–small cell lung cancer.

James Luke Godwin, MD, recaps recent advancements in frontline metastatic castration-sensitive prostate cancer and highlights emerging agents with potential in this space.

Adam Brufsky, MD, PhD, comments the FDA approval of MYL-1401O and discusses the adoption of biosimilars in oncology.

Sunil Verma, MD, shares his insight on the approval of MYL-1401O, as well as his excitement for the future development of biosimilars across oncology.